The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining treatment paradigms through ...

Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to take on the dominance of MSD’s Keytruda (pembrolizumab) in solid tumour ...

Liminatus Pharma is a preclinical oncology company focused on a CD47 antibody. Check out why I see little reason for ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company is advancing Temab-A across multiple tumor types targeting c-Met, with the goal of establishing it as a ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for ...

New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, ...

AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight its potential. Click for my ANAB update.

The use of PD-1 checkpoint inhibitor therapy in metastatic TNBC has been shown to improve survival in the first-line setting in combination with chemotherapy in a subset of patients with PD-L1 CPS ...

(NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, ...